DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans.

In the present study, we tested 19 Caucasian and 28 Black American narcoleptics for the presence of the human leucocyte antigen (HLA) DQB1*0602 and DQA1*0102 (DQ1) genes using a specific polymerase chain reaction (PCR)-oligotyping technique. A similar technique was also used to identify DRB1*1501 and DRB1*1503 (DR2). Results indicate that all but one Caucasian patient (previously identified) were DRB1*1501 (DR2) and DQB1*0602/DQA1*102 (DQ1) positive. In Black Americans, however, DRB1*1501 (DR2) was a poor marker for narcolepsy. Only 75% of patients were DR2 positive, most of them being DRB1*1503, but not DRB1*1501 positive. DQB1*0602 was found in all but one Black narcoleptic patient. The clinical and polygraphic results for this patient were typical, thus confirming the existence of a rare, but genuine form of DQB1*0602 negative narcolepsy. These results demonstrate that DQB1*0602/DQA1*0102 is the best marker for narcolepsy across all ethnic groups.

[1]  C. Guilleminault,et al.  A novel HLA DR17,DQ1 (DQA1-0102/DQB1-0602 positive) haplotype predisposing to narcolepsy in Caucasians. , 1993, Sleep.

[2]  S. Weissman,et al.  Application of cDNA selection techniques to regions of the human MHC. , 1993, Genomics.

[3]  E. Albert,et al.  A deletion in the second exon of an HLA-DRB1 allele found in a DR2-negative narcolepsy patient. , 1993, Human immunology.

[4]  G. Nepom,et al.  HLA-DQ allelic polymorphisms constrain patterns of class II heterodimer formation. , 1993, Journal of immunology.

[5]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[6]  L. Baxter‐Lowe,et al.  Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-DQw1. , 1992, Tissue antigens.

[7]  W. Klitz,et al.  Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. , 1992, Journal of immunology.

[8]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 1991. , 1992, Vox sanguinis.

[9]  P. Stastny,et al.  HLA class II haplotypes in Amerindians and in black North and South Americans. , 1991, Tissue antigens.

[10]  E. Thorsby,et al.  Novel HLA-DR2 and -DR3 haplotypes among Norwegian Caucasians. , 1991, Tissue antigens.

[11]  J. Ragoussis,et al.  Map of the human MHC. , 1991, Immunology today.

[12]  H. Erlich,et al.  MHC class-II molecules and autoimmunity. , 1991, Annual review of immunology.

[13]  M. Kryger,et al.  Genetic heterogeneity in narcolepsy , 1990, The Lancet.

[14]  M. Billiard,et al.  CSF immune variables in patients with narcolepsy , 1990, Acta neurologica Scandinavica.

[15]  C. Guilleminault,et al.  FAMILIAL PATTERNS OF NARCOLEPSY , 1989, The Lancet.

[16]  T. Juji,et al.  HLA Antigens in 206 Japanese Patients with Narcolepsy and 46 Patients with Essential Hypersomnia , 1989 .

[17]  A. Cambon-Thomsen,et al.  Recombinations in the HLA system. , 1989, Tissue antigens.

[18]  H. Inoko,et al.  No difference in the nucleotide sequence of the DQ beta beta 1 domain between narcoleptic and healthy individuals with DR2,Dw2. , 1989, Human immunology.

[19]  M. Mitler,et al.  HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. , 1988, Clinical immunology and immunopathology.

[20]  T. Juji,et al.  HLA in Narcolepsy , 1988, Springer Berlin Heidelberg.

[21]  G. Mueller‐Eckhardt,et al.  Narcolepsy and HLA in the Federal Republic of Germany: Population and Family Data , 1988 .

[22]  H. Inoko.  DNA Typing in Narcolepsy , 1988 .

[23]  K. Tokunaga,et al.  HLA-Linked Complement Markers in Narcolepsy , 1988 .

[24]  T. Juji,et al.  Immunological Features of Narcolepsy in Japan , 1988 .

[25]  R. Vaughan,et al.  HLA in Narcolepsy/Cataplexy in the United Kingdom , 1988 .

[26]  J. Strominger,et al.  Human class II major histocompatibility complex genes and proteins. , 1988, Annual review of biochemistry.

[27]  J. Spire,et al.  HLA antigens in narcolepsy , 1987, Neurology.

[28]  W. Klitz,et al.  Disequilibrium pattern analysis. II. Application to Danish HLA A and B locus data. , 1987, Genetics.

[29]  G. Mueller‐Eckhardt,et al.  HLA and narcolepsy in a German population. , 2008, Tissue antigens.

[30]  R. Germain,et al.  Influence of allelic polymorphism on the assembly and surface expression of class II MHC (Ia) molecules , 1985, Cell.

[31]  J. D. Capra,et al.  Allelic polymorphism and transassociation of molecules encoded by the HLA-DQ subregion. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Satake,et al.  EXTRAORDINARY ASSOCIATION BETWEEN HLA-DR2 AND NARCOLEPSY , 1985, The Lancet.

[33]  R. Vaughan,et al.  GENETIC MARKERS IN NARCOLEPSY , 1984, The Lancet.

[34]  Charles Auffray,et al.  The class II molecules of the human and murine major histocompatibility complex , 1984, Cell.

[35]  J. Parkes,et al.  Genetic study of narcoleptic syndrome. , 1978, Journal of medical genetics.

[36]  C. Guilleminault,et al.  A FAMILY STUDY OF 50 REM NARCOLEPTICS , 1974, Acta neurologica Scandinavica.

[37]  B. Roth,et al.  Heredofamilial aspects of narcolepsy and hypersomnia. , 1972, Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie.

[38]  Daly Dd,et al.  Hereditary aspects of narcolepsy. , 1960 .

[39]  Daly Dd,et al.  A family with narcolepsy. , 1959 .

[40]  G. Magnussen,et al.  ON NARCOLEPSY: I. FAMILIAL NARCOLEPSEY , 1942 .